Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Eli Lilly
(NY:
LLY
)
826.71
+1.09 (+0.13%)
Official Closing Price
Updated: 7:00 PM EST, Dec 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Eli Lilly
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
LeapFrog Investments raises more than $1 billion for impact health investing
November 27, 2024
LeapFrog Investments said this week it has raised more than $1 billion in a new investment fund that targets high-impact health and financial-services
Via
Equities.com
Verge Genomics Announces Milestones in Collaboration with Lilly to Discover and Develop Novel Treatments for ALS
November 20, 2024
From
Verge Genomics
Via
GlobeNewswire
Can Roche Challenge Lilly and Novo in the Weight Loss Market?
October 22, 2024
One Wall Street analysts recently singled out a drug from pharma company Roche as a threat to Eli Lilly's oral GLP-1 candidate.
Via
MarketBeat
Why Eli Lilly Stock Is Soaring—and How It Plans to Stay on Top
October 13, 2024
Eli Lilly is the most valuable pharmaceutical company in the world. I believe the company has what it takes to stay there.
Via
MarketBeat
Top 3 Stocks with Explosive Call Option Activity: What to Watch
October 10, 2024
Three stocks reported a surge in call option buying recently, showing investors that there could be a path to more upside potential, analysts agree
Via
MarketBeat
Don’t Sleep on Skye Bioscience—This Weight Loss Drug Could Soar
October 09, 2024
Skye Bioscience has incredible potential upside, according to Wall Street analysts. It is striving to make a new weight loss drug, that could work with GLP-1s.
Via
MarketBeat
Hims & Hers Stock Joins S&P 600: Is More Upside on the Horizon?
October 08, 2024
There is now a new reason to look into Hims & Hers stock for additional upside, including the new addition to the S&P 600 index alongside double-digit growth.
Via
MarketBeat
Topics
Stocks
Exposures
US Equities
3 Momentum Trades Too Good Pass Up
October 02, 2024
Check out these three stocks each up over 60% in the past twelve months. Their strong paths for growth can help keep their momentum stories going.
Via
MarketBeat
Topics
ETFs
Transforming Alzheimer’s Treatment: Innovative Combinations to Boost Cognition
October 01, 2024
Via
Investor Brand Network
Transforming Alzheimer’s Treatment: Innovative Combinations to Boost Cognition
October 01, 2024
EQNX::TICKER_START (NYSE:ANVS),(NYSE:LLY),(NYSE:PFE),(NYSE:NVO),(NASDAQ:ABBV) EQNX::TICKER_END
Via
FinancialNewsMedia
Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
September 24, 2024
Novo Nordisk has received both good and bad news recently when it comes to weight loss and diabetes drugs. So, where does the firm stand now?
Via
MarketBeat
As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse
September 24, 2024
EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:NTRBW),(NYSE:TEVA),(NYSE:LLY),(NYSE:NVS),(NASDAQ:AMRX) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
Product Safety
As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse
September 24, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Kalm Therapeutics Hires Former GSK Director Dr. Tomoko Maeda-Chubachi as Chief Medical Officer
September 16, 2024
Huntsville, Alabama--(Newsfile Corp. - September 16, 2024) - Kalm Therapeutics (Kalm Tx) is pleased to announce the appointment of Dr....
Via
Newsfile
Harvest ETFs (TSX: LLYH, LLYH.U, AMZH, AMZH.U, MSFH, MSFH.U, NVDH, NVDH.U, LLHE, LLHE.U, AMHE, AMHE.U, MSHE, MSHE.U, NVHE, NVHE.U ) Closes the Market
September 11, 2024
Toronto, Ontario--(Newsfile Corp. - September 11, 2024) - Michael Kovacs, President and CEO, Harvest ETFs, ("Harvest" or the "Company") and...
Via
Newsfile
Topics
ETFs
Invest While You Can: Pullbacks on These 3 Stocks Won’t Last Long
September 10, 2024
Three stocks stand out for investors to consider as they recently had big selloffs. There are fundamental reasons to believe that these discounts won't last
Via
MarketBeat
Topics
Economy
Exposures
Economy
Interest Rates
Is Merck Stock Undervalued After Its Colossal Earnings Growth?
September 07, 2024
Merck has seen its earnings invert over the past 12 months, driving earnings grow in its sector. What's going on with this pharma giant?
Via
MarketBeat
The GLP-1 Products and Players - Expanding a new Era of Pharmaceutical Products for Diabetes and Weight Loss
August 28, 2024
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - August 28, 2024) - Investorideas.com, a go-to investing platform covering health and...
Via
Newsfile
Eli Lilly’s Path to the Next Trillion Market Capitalization
August 26, 2024
Eli Lilly and Co. (NYSE: LLY) is a pharmaceutical giant that's made headlines for its GLP-1/GIP weight loss drug Tirzepatide, aka Mounjaro, for Type 2 diabetes.
Via
MarketBeat
Merck's Stock Dip Offers a Buying Opportunity: Here’s Why
August 20, 2024
Global big pharmaceutical company Merck & Co. Inc. (NYSE: MRK) shares sank 9% following its Q2 2024 earnings release. Merck beat top and bottom line estimates,
Via
MarketBeat
Topics
Intellectual Property
Exposures
Intellectual Property
MarketBeat Week in Review – 8/5 - 8/9
August 10, 2024
Stocks were looking for direction to end the week, but next week may bring more volatility with the latest reading on inflation and the start of retail earnings
Via
MarketBeat
Topics
Economy
Exposures
Economy
Interest Rates
Novo Nordisk's Shares Go on a Rollercoaster Ride After Earnings
August 09, 2024
Novo Nordisk fell over 8% after its earnings release but recovered nearly all of those losses the next day. It needs to increase supplies of semaglutide.
Via
MarketBeat
Topics
ETFs
It's Too Soon to Buy the Dip in Weight Loss Drugmakers
August 09, 2024
Obesity drugs are a hot market and one still accelerating as new treatments are approved and usage widens. The bad news is that much of the growth is priced in.
Via
MarketBeat
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Release Promising Clinical Data As Global Alzheimer’s Disease Therapeutics Market Grows
August 07, 2024
Via
Investor Brand Network
Amgen's MariTide Weight Loss Potential: Stock Outlook
August 07, 2024
Amgen's shares fell 2.4% after-hours trading due to a mixed earnings release. MariTide, the company's weight loss drug, is in Phase II FDA trials.
Via
MarketBeat
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Lucrative Incentive for Biotechs as Global Alzheimer’s Disease Therapeutics Market Forecasted to Reach $30.8 Billion By 2033
August 06, 2024
EQNX::TICKER_START (NYSE:ANVS),(NYSE:PFE),(NYSE:LLY),(NYSE:GSK),(NYSE:NVO) EQNX::TICKER_END
Via
FinancialNewsMedia
Lucrative Incentive for Biotechs as Global Alzheimer's Disease Therapeutics Market Forecasted to Reach $30.8 Billion By 2033
August 06, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected
July 25, 2024
EQNX::TICKER_START (NASDAQ:TNXP),(NYSE:PFE),(NYSE:LLY),(NYSE:ABBV),(NASDAQ:AXSM) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
Product Safety
Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected
July 25, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Positive News is Driving This Cancer Drug Maker’s Stock Higher
July 15, 2024
IDEAYA Biosciences stock is up more than 16% on positive treatment data in a Phase 2 clinical trial, but after a 76% run-up, IDYA stock may need a breather
Via
MarketBeat
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.